Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Quest Diagnostics IncorporatedNYSE: DGX
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables grows, but more slowly than its trailing trend
Q3 FY2026 accounts receivables of $49M (cash outflow) rose 28.9% year over year, behind the +210.7% change in trailing-twelve-month accounts receivables. Sequentially, it fell 38.0% from the prior quarter.
Context
- Accounts receivables amounted to 1.0% of revenue in FY2025, up 0.2 pp from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +28.9% toward the trailing-twelve-month pace of +210.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (106M) USD
- Year-over-year change
- -49.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (106M) | -49.3% |
| FY2024 | 2024-12-31 | (71M) | -373.3% |
| FY2023 | 2023-12-31 | (15M) | -106.1% |
| FY2022 | 2022-12-31 | 246M | +203.7% |
| FY2021 | 2021-12-31 | 81M | — |
Accounts Receivables vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's LTM Sep 2026 accounts receivables of $261M is the largest of the 9 companies compared; the peer median is $52.9M.
- Its year-over-year change of +210.7% is the highest of 9, against a peer median of -6.3%.
- Accounts receivables amounts to 2.2% of revenue for DGX, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $261M | +210.7% | — | 2.2% | |
| LTM Jun 2026 | $240.4M | -2961.9% | — | 1.7% | |
| LTM Jun 2026 | $157M | +34.2% | +108.0% | 3.5% | |
| LTM Jun 2026 | $109.63M | -510.4% | — | 4.0% | |
| LTM Sep 2026 | $70.6M | +155.1% | — | 5.5% | |
| LTM Jul 2026 | $35.21M | -46.7% | — | 1.2% | |
| LTM Sep 2026 | $19.55M | +184.3% | -31.8% | 0.8% | |
| LTM Jun 2026 | $7.31M | -67.7% | — | 0.3% | |
| LTM Jun 2026 | $5.68M | +71.1% | — | 3.4% | |
| Peer median (excluding DGX) | $52.9M | -6.3% | +38.1% | 2.6% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.08B | 1.02B | 908M | 921M | 1.05B |
| Depreciation & Amortization | 408M | 437M | 439M | 493M | 570M |
| Deferred Income Tax | (57M) | 1M | (49M) | 13M | 105M |
| Stock-Based Compensation | 79M | 77M | 77M | 88M | 88M |
| Change in Working Capital | 87M | 119M | (145M) | (201M) | 50M |
| Accounts Receivables | 81M | 246M | (15M) | (71M) | (106M) |
| Inventory | (20M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 35M | (149M) | (55M) | (67M) | 129M |
| Other Working Capital | (9M) | 22M | (75M) | (63M) | 27M |
| Other Non-Cash Items | (364M) | 69M | 42M | 20M | 27M |
| Operating Cash Flow | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B |
| Capital Expenditures | (403M) | (404M) | (408M) | (425M) | (527M) |
| Acquisitions (Net) | 424M | (144M) | (611M) | (2.16B) | (101M) |
| Purchases of Investments | (3M) | (5M) | 0 | 0 | 0 |
| Sales of Investments | 403M | 5M | 0 | 0 | 0 |
| Other Investing Activities | (400M) | 5M | (42M) | 41M | (3M) |
| Investing Cash Flow | 21M | (543M) | (1.06B) | (2.55B) | (631M) |
| Debt Repayment | (2M) | (2M) | 748M | 1.54B | (602M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79M |
| Common Stock Repurchased | (2.2B) | (1.41B) | (275M) | (151M) | (450M) |
| Dividends Paid | (309M) | (305M) | (314M) | (331M) | (353M) |
| Other Financing Activities | (30M) | (17M) | 1M | 23M | (62M) |
| Financing Cash Flow | (2.54B) | (1.73B) | 160M | 1.08B | (1.39B) |
| Effect of Forex Changes | 0 | 0 | 0 | (7M) | 4M |
| Net Change in Cash | (286M) | (557M) | 371M | (137M) | (129M) |
| Free Cash Flow | 1.83B | 1.31B | 864M | 909M | 1.36B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.